Navigation Links
Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies

inelli Chiesi Farmaceutici SpA +39 0521 279 084 hullman@fkhealth.com L.Storari@chiesigroup.com M.Zaninelli@chiesigroup.com

CONTACT: Dey, L.P. Media Line, +1-800-755-5560, ext. 8363; Harriet Ullmanof Feinstein Kean Healthcare, +1-617-761-6776, ; LindaStorari, +39 0521 279 620, , or Massimo Zaninelli,+39 0521 279 084, , both of Chiesi FarmaceuticiSpA hullman@fkhealth.com L.Storari@chiesigroup.com M.Zaninelli@chiesigroup.com

Web site: http://www.dey.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
2. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
3. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
4. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
5. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
6. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
7. Baxter Presents Phase I Inhaled Insulin Study Results at Respiratory Drug Delivery Conference
8. DVT Awareness Survey Findings: Heart and Respiratory Patients
9. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
10. New Research Results Show That Investigational Drug Phenoxodiol Targets Cancer Protein, Causing Cancer Cell Death
11. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
Post Your Comments:
(Date:10/7/2008)...enu Expanded to Eight On-Demand Tests for Use on t...stem, SUNNYVALE, Calif., Oct. 7 /PRNewswire-First...e release of Xpert(TM) vanA/vanB as a European CE,...n Vitro Diagnostic,Medical Devices. The test deliv... genes most commonly associated with vancomycin-re...
(Date:10/6/2008)... and CHIPPENHAM, England, October 7 /PRNewswire-Fi...Mothers Index: 4565) and Vectura,Group plc ("Vectu...tudies,evaluating the efficacy, safety and tolerab...f the European Respiratory Society (ERS) in Berlin...ronium bromide), a novel,inhaled long-acting musca...
(Date:10/6/2008)... Data Presented at the American College of Gastroe...eting, ORLANDO, Fla., Oct. 6 /- Comb... the American College of Gastroenterology Annual,S...ated that TAK-390MR,resulted in higher healing rat...re grades of erosive esophagitis (EE). TAK-390MR c...
(Date:10/6/2008)... technology opens the door to the understanding of...betes, ageing and cancer, BILLERICA, Mass., Oct. ...ced the release of the first ever analytical instr... oxygen consumption and cytoplasmic,glycolysis in ...rs tools,for measuring cellular bioenergetics have...
Breaking Medicine Technology:Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 2Takeda's Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed 3Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3Research cautions to catch and release in less than 4 minutes 597 1Research cautions to catch and release in less than 4 minutes 597 2Wyeth Announces the Election of Robert M Amen to Its Board of Directors 2260 1Statement of DePuy Orthopaedics Inc Regarding Agreement with U S Attorneys Office 2258 1Statement of DePuy Orthopaedics Inc Regarding Agreement with U S Attorneys Office 2258 2Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2256 1Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2256 2Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2256 3Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2256 4Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors 2256 5
...XT-ALIGN: left; tab-stops: 0in",align="left"> , ,<...in; mso-list: l1 level1 lfo2">, <span style=,"FONT...di-font-weight: bold">,Independent Japanese study ... conventional therapy , , , ,<li style=,"MARGIN...level1 lfo2">, <span style=,"FONT-SIZE: 11pt; FONT...
...007 –,Merck Serono S.A. (virt-x: SEO) and it...) announced today that Professor,Fabrizio Stocchi,...ase III trial of safinamide as an adjunctive treat...rsquo;s disease (PD),patients at the American Acad... Boston from 28 April to 5 May 2007. , The abstrac...
Other Medicine Technology:Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 2Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 3Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 4Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 5Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 6Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 7Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 8Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 9Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 10Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 11Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study 12Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 2Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 3Merck Serono Announces Presentation of Phase III Clinical Data on,Safinamide in Parkinson’s Disease at the American Academy of,Neurology 59th Annual Meeting 4
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...the US are at an advanced stage but it could be a ...ays an expert involved in the project. // "You mu...e large numbers of people involved and we have to ...ds. We are on the way but it will be a while befor...
... by extreme and irrational fear of simple things o...ctly what causes this. // To overcome this scient...l in the trial stage. The remedy developed by a S...ns a human hormone called cortisol, which the body...
... testicular cells obtained from male mice into emb...at have the remarkable ability to transform into o...the same could be achieved in humans, helping sett...ith the derivation of embryonic stem cells from un...
...on, Iowa, is currently witness to the combined res...on with the money // and Technological prowess of...n the ubiquitous sorghum crop that is the only suc... The joint venture, targeting sorghum, a widely kn...
Other Medicine News:Health News:HIV Vaccine Field Trials In Advanced Stage 2
...eica ASP200 is an advanced smart processor for par...ne histopathology applications. Proven and enhance... smart operating software are the hallmark of the ...ed and the software includes a variety of SMART fe...
The electronic, motorized rotary microtomes are designed for all applications of paraffin, semi-thin (HM 360), and hard specimens in clinical, research, and industrial labs. These instruments display
...eica RM2255 rotary microtome, designed for fully m...bedded specimens, offers a broad application spect...ory. This microtome meets the requirements of user...c microtome for their laboratory. The entire acces...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user.
Medicine Products: